Date: 2015-03-30
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: Eli Lilly (USA - IN)
Product: LY3023414
Action
mechanism: PI3K/mTOR inhibitor LY3023414 is a small molecule inhibitor of certain class I phosphoinositide 3-kinase (PI3K) isoforms and mammalian target of rapamycin kinase (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. The PI3K/mTOR pathway is upregulated in a variety of tumor cells and plays a key role in promoting cancer cell proliferation, and survival, motility and resistance to chemotherapy and radiotherapy. mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion; therefore, this agent may be more potent than an agent that inhibits either PI3K or mTOR alone. In addition, LY3023414 may inhibit DNA-dependent protein kinase (DNA-PK), thereby inhibiting the ability of tumor cells to repair damaged DNA. DNA-PK is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks.
Disease: prostate cancer
Therapeutic area: Cancer - Oncology
Country: USA
Trial
details: The main purpose of this study is to evaluate the safety and effectiveness of LY3023414 in combination with enzalutamide in men with prostate cancer. (NCT02407054)
Latest
news: * On March 30, 2015, a Phase 2 trial sponsored by Eli Lilly was published on the NIH website ClinicalTrials.gov LY3023414 and is currently recruiting participants.
